Sign In
Buy GLP
$48.45
-0.81 (-1.64%)
At Close: Jun 03, 2026
- RT-114 yielded a relative bioavailability of 111% compared to PG-102 delivered subcutaneously with comparable PK profiles, meeting the primary endpoint of demonstrating bioequivalenc e –
Silo Pharma Achieves Key Milestone with First Dosing in IND-Enabling GLP Study for SPC-15 as a Groundbreaking PTSD Treatment
08:40am, Wednesday, 26'th Mar 2025
Preclinical Data to Support Advancement Toward First-in-Human Clinical Trials SARASOTA, FL, March 26, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a dev
Structure Therapeutics CEO on latest GLP-1 developments
06:26pm, Monday, 24'th Mar 2025
Ray Stevens, Structure Therapeutics CEO, joins 'Fast Money' to talk advancements in weight loss drugs and the development of a GLP-1 pill.
Structure: A Lot Riding On Next Data Readout For Oral GLP-1 Candidate
09:28am, Thursday, 20'th Mar 2025
Structure Therapeutics' stock has declined over 40% since last year, but its differentiated technology platform and promising drug pipeline still support a "Buy" rating. Structure's lead candidate, al
Is Viking Therapeutics the Next Blockbuster GLP-1 Stock?
08:46am, Tuesday, 18'th Mar 2025
When it comes to clinical weight-loss treatments, GLP-1 therapies have taken the medical sector by storm. What started as off-label use by celebrities and social media influencers for cutting weight b
MIAMI and JERUSALEM, March 17, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) and Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of oral peptides and proteins replacement therap
ALAMEDA, Calif.--(BUSINESS WIRE)--Vivani Medical, Inc. (NASDAQ: VANI) (“Vivani” or the “Company”), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug impla
Giftify, Inc. Reports Surge in Pharmacy Retailer Gift Card Demand Following GLP-1 Medication Savings Initiative
08:30am, Wednesday, 12'th Mar 2025
Record Inventory Increase Meets Growing Consumer Demand for Healthcare Cost-Saving Solutions Surge Driven by Ozempic and Zepbound Prescription Savings Opportunities Combined with Seasonal Health Produ
RoadFlex Announces Strategic Fuel Partnership with Global Partners, a Leader in Energy Solutions
11:00am, Tuesday, 11'th Mar 2025
WALTHAM, Mass.--(BUSINESS WIRE)-- #roadflex--RoadFlex, the leader in fuel risk management and fleet card solution, today announced a new strategic partnership with Global Partners LP (NYSE: GLP). This
Despite Challenges Novo Nordisk Plans to Crush GLP-1 Competitors
11:03am, Monday, 10'th Mar 2025
Novo Nordisk A/S NYSE: NVO has declared that its GLP-1 drugs for chronic obesity, under the brands Ozempic and Wegovy, are no longer in short supply. This caused the United States Food and Drug Admini
Teladoc Health Adds GLP-1 Self-Pay Option to Comprehensive Weight Care
08:31am, Thursday, 06'th Mar 2025
Pharmacy Integration with Gifthealth to Extend Seamless Support for FDA-Approved Medication to Obesity Program Members Without GLP-1 Coverage Pharmacy Integration with Gifthealth to Extend Seamless Su
Novo Nordisk to explore how GLP-1 drugs can help patients with addiction
04:28am, Thursday, 06'th Mar 2025
Novo Nordisk will explore how GLP-1 drugs potentially could help patients struggling with addiction, its head of development Martin Holst Lange told an online press conference on Thursday.
Hims & Hers' Fall From Grace Is Warranted - Still No Margin Of Safety
11:47am, Monday, 03'rd Mar 2025
HIMS' steep correction is well warranted, given the expensive valuations and the headwinds from the now available FDA-approved GLP-1 therapies. However, we believe that the end of GLP-1 shortage is a
Global Partners LP Files 2024 Annual Report on Form 10-K
04:10pm, Friday, 28'th Feb 2025
WALTHAM, Mass.--(BUSINESS WIRE)--Global Partners LP (NYSE: GLP) today announced that its Annual Report on Form 10-K for the year ended December 31, 2024, was filed with the U.S. Securities and Exchang
Madrigal Pharmaceuticals: Rezdiffra First-Mover Advantage Gains Traction (Upgrade)
02:29pm, Friday, 28'th Feb 2025
Madrigal Pharmaceuticals, Inc.'s Rezdiffra had a strong launch with $103.3M in Q4 sales and solid liquidity, but GLP-1 competition from Novo and Lilly poses significant future challenges. Madrigal's P
